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1. Introduction 
Bowel dysfunction is common in patients with neurological diseases. Its prevalence ranges 
from 30% to 60% in patients with cerebrovascular diseases and new-onset constipation 
occurs in 55% of patients after a stroke (Su et al., 2009; Harari et al., 2004; Robain et al., 2002; 
Bracci et al., 2007). In Multiple Sclerosis (MS) constipation is a frequent bowel symptom and 
it has been observed in up to 73% of patients (Crayton et al., 2004; Gulick et al., 2011; Wiesel 
et al., 2000). In Parkinson’s disease (PD) constipation is one of the most frequent non-motor 
features, believed to occur in over 50% of patients (Wood et al., 2010; Pfeiffer et al., 2003; 
Wolters et al., 2009). Disorders of the anorectal sphincters consist of incontinence or 
difficulty in expelling faeces. Constipation is almost always associated with slowed bowel 
transit. It may be due to sphincter incoordination in relation to the detrusor mechanism or to 
detrusor weakness causing loss of propulsive force (Swash et al., 2001). Constipation may 
have a significant impact on quality of life and would restrict patient’s social activities, 
increasing levels of anxiety and depression, so that symptoms’ management is critically 
important (Ng et al., 2005). This review describes the possible pathogenesis of constipation 
in neurological disorders, pharmacological therapies available for constipation and 
management approaches that may increase the likelihood of satisfactory treatment 
outcomes. 
2. Constipation in stroke 
Constipation is defined as two or fewer bowel movements per week, the need to manipulate 
the rectum digitally to facilitate defecation all or most of the time, and/or use of laxatives, 
enemas or suppositories more than once a week (Hinds et al., 1990). Medical complications 
after acute stroke are common, ranging from 28% to 96% (Hong et al., 2008). Bowel 
dysfunction are the most frequent gastrointestinal complaints with a negative impact on 
patients’ quality of life, restricting their social activities (Bracci et al., 2007; Su et al., 2009). 
The prevalence of constipation after stroke varies from 30% to 60% (Harari et al., 2004). 
New-onset constipation is seen in 55% of patients within a month after first stroke, strongly 
relating to disability. Its development may predict a poor outcome at 12 weeks in patients 
with moderately severe stroke (Su et al., 2009). 
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New onset constipation occurs in 30% of hemiplegic patients and has no relationship with 
the hemispheric side or with the severity of stroke even if a trend of reduced risk of 
constipation is described in patients with ischemic event and less widespread lesion (Bracci 
et al., 2007). Risk factors for constipation among stroke patients include use of a number of 
different drugs, dehydration, older age and immobility (Bracci et al., 2007; Su et al., 2009; 
Kumar et al., 2010). For the elderly, acute hospitalization is at higher risk to develop 
constipation than in other age groups (Cardin et al., 2010). The highest risk of new-onset 
constipation occurs on one week after stroke, so that early intervention may prevent the 
development of bowel dysfunction (Su et al., 2009). Treatment with nitrates and 
antithrombotics represents an independent risk factor for developing chronic constipation. 
Nitrates may cause constipation due to the inhibitory role in gut motility secondary to the 
release of nitric oxide. Antithrombotic drugs, such as acetyl salicylic acid (ASA), indobufen 
and ticlopidine, have been reported to be associated with bowel dysfunction. ASA and 
NSAID are more frequently associated with constipation probably via inhibition of the 
propulsive activity by preventing the release of prostaglandins. Indobufen and ticlopidine 
are usually associated with diarrhea. No significant association has been described between 
new onset constipation and ACE inhibitors or anticoagulants (Bracci et al., 2007). 
Anticholinergic drugs, such as antipsychotics, tricyclic antidepressants or oxybutynin, 
significantly increase the risk of faecal incontinence in patients with stroke, decreasing gut 
motility and causing constipation with overflow incontinence (Kumar et al., 2010). The use 
of diuretics such as mannitol or furosemide is associated with new-onset constipation (Su et 
al., 2009). 
Bed rest and immobility contribute to constipation onset. Hypovolemia, as a result of 
dysphagia and/or impaired thirst mechanisms, is another risk factor. Between 37% and 78% 
of patients with stroke develop dysphagia, with a restriction of oral intake of dietary fibre 
and a high risk of undernutrition and dehydration (Ullman et al., 1996; Kumar et al., 2010; 
Su et al., 2009). 
It is well known that the central nervous system (CNS) takes part in the control of visceral 
functions and its damage can lead to gastrointestinal impairment (Bracci et al., 2007). 
Lesions affecting the pontine defecatory centre may disrupt the sequencing of sympatical 
and parasympathical components of defecation, and impair the coordination of the 
peristaltic wave and the relaxation of the pelvic floor and external sphincter (Ullman et al., 
1996). Constipation could be a clinical manifestation of spinal cord stroke as a consequence 
of pelvic autonomic dysfunction (Sakakibara et al., 2008). 
3. Constipation in MS 
Constipation may represent an early symptom of MS and large bowel impairment can 
precede the onset of MS by many years (Lawthom et al., 2003; Chellingsworth et al., 2003). 
Bowel dysfunctions are multifactorial and include neurological impairment, behavioural 
problems, inappropriate toilet facilities, side effects of drugs or coexistent disorders. A 
multidisciplinary approach is the best way to deal with this symptom. Bowel symptoms 
should be carefully treated because sometimes helping constipation can precipitate faecal 
incontinence. Certain patients would prefer to remain constipated if incontinence is thereby 
avoided (Wiesel et al., 2001). Gastrointestinal symptoms are common in patients with MS 
and are much more frequent than in the general population (Wiesel et al., 2001). The 
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prevalence of constipation, alone or in association with faecal incontinence, ranges between 
35% to 73%, depending on definitions and selection (Crayton et al., 2004; Gulick et al., 2011; 
Wiesel et al., 2000; Bakke et al., 1996). There is no difference between male and female 
patients regarding constipation frequency that presents a strong correlation with disability 
and disease duration (Hinds et al., 1990). Bladder and bowel dysfunctions have a significant 
role in psychosocial disability of MS patients, affecting quality of life (Wiesel et al., 2001). 
Pathophysiology of constipation in MS is poorly understood. Central nervous system 
lesions, related to the disease process, may be responsible in some cases, affecting the 
extrinsic neurological control of gut and sphincter function. Autonomic nervous system 
impairment, specifically involving parasympathetic pathways, or some systemic mechanism 
not well known, similar to that which causes fatigue in MS, have been proposed (Fowler et 
al., 1997; De Seze et al., 2001; Guinet et al., 2011). Some authors have suggested a cerebral 
involvement or a motor spinal pathways failure as a cause of constipation in MS (Haldeman 
et al., 1982; Mathers et al., 1990). Abnormalities of colonic activity and prolonged colonic 
transit time have been demonstrated in some patients, and difficult defecation due to failure 
to relax the pelvic floor muscles has been found in others (Mark et al., 1999). Whether pelvic 
floor incoordination shown in some patients with MS should be regarded as a behavioural 
phenomenon, as in non-neurological constipation, or as related to the MS is yet unknown 
(Wiesel et al., 2000). Some authors associated large bowel dysfunction to demyelinating 
lesions of the conus medullaris, even if the role of more proximal lesions cannot be ruled out 
(Taylor et al., 1984). Other features connected to MS, compromising pelvic floor function 
and visceral motility, may contribute to constipation: muscle weakness, fatigue, spasticity 
and poor mobility. Also some medications, commonly used to manage different MS 
symptoms, such as anticholinergics, antidepressants, opiates and muscle relaxants, can 
affect bowel function (Wiesel et al., 2001; Fowler et al., 1997; Nordenbo et al., 1996; Gill et al., 
1994). Finally, psychological factors or behavioural problems may also affect toileting 
(Wiesel et al., 2000). 
4. Constipation in spinal cord injury 
Bowel dysfunction is one of the major sequelae of spinal cord injury (SCI), with a severe 
impact on long-term quality of life, also increasing anxiety and depression. The prevalence 
of constipation in subjects with SCI is 20-58% (Ng et al., 2005). It is well known that 
constipation in SCI is due to prolonged colonic transit time. In SCI the extrinsic neural 
control is lost with an altered sympathic function (Winge et al., 2003). There is a clear 
association between constipation and the presence of a higher level of injury, as 
demonstrated by a mouth-to-cecum transit time prolonged in quadriplegics rather than 
paraplegics (Rajendran et al., 1992). Patients with cauda equina lesions may have an atonic 
bowel and develop severe and chronic constipation (Winge et al., 2003). 
The variation in constipation prevalence in patients with different levels of neurologic 
deficit are related to different factors, such as attenuated gastrocolonic reflex, weakness of 
abdominal and perineal musculature, anorectal dysfunction and body immobilization (Stark 
et al., 1999; Ng et al., 2005). 
Treating constipation in SCI subjects can be demanding. The usual management is a 
combination of bulking agents and scheduled enemas. Bowel training is used to evacuate 
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the colon at regular intervals and an adequate fiber and fluid intake maintains bowel 
movements in a soft and bulky form. Shortly after breakfast, a rectal suppository and digital 
stimulation of the anorectum are used to induce reflex evacuation. These treatments usually 
leads to a daily planned evacuation. When they fail, prokinetic agents, parasympathetic 
nerve stimulators or colostomy can be used (Stark et al., 1999). In selected patients, transanal 
irrigation improves bowel function, compared with conservative management (Christensen 
et al., 2006). 
5. Constipation in Parkinson Diseases (PD) 
Bowel dysfunction is the most commonly observed non-motor feature of PD and it is a 
major factor in determining quality of life, progression of disability and nursing care (Hely 
et al., 2005). Some authors found constipation in 29% of patients (Edwards et al., 1991). 
However this symptom is under-recognised and under-treated but it has the potential to be 
more debilitating than motor features. The reason of this could be the patients’ unawareness 
that these symptoms are linked to PD. Constipation is frequently reported as a prominent 
complaint before the onset of motor symptoms in about 50% of patients (Wood et al., 2010). 
Recently, an epidemiological study revealed an association between frequency of bowel 
movements and the risk of developing PD. Those patients with an initial finding of 
constipation were at a 3-fold increased risk of developing PD after 10 years from the initial 
report of constipation (Abbott et al., 2001). Bowel dysfunction can occur across all stages of 
PD but often occurs earlier during disease course and it might precede motor symptoms 
onset by more than a decade, correlating closely with the progression of Lewy pathology 
(Korczyn et al., 1990; Chaudhuri et al., 2009). 
Bowel dysfunction can consist of both slowed colonic transit with consequent reduced 
bowel-movement frequency and difficulty with the act of defecation itself with excessive 
straining and incomplete emptying (anorectal dysfunction). Anorectal dysfunction is the 
more prevalent form of bowel impairment in PD Recognition can lead to earlier and 
potentially more effective therapeutic intervention (Pfeiffer et al., 2003). 
An efficient and successful defecation requires the coordinated contraction and relaxation of 
several muscles. Defecography, anorectal manometry and analsphincter electromyography 
have been used to study defecation in PD, showing different abnormalities (Stocchi 2000). In 
a group of patients, anorectal dysfunction caused a paradoxical contraction of voluntary 
sphincters during defecation, which is believed to be a type of focal dystonia (Mathers et al., 
1989). 
Control of gastrointestinal function is complex and involves components of the central, 
autonomic, and enteric nervous systems (Pfeiffer et al., 2003). Changes in parasympathetic 
autonomic supply to the gut could certainly account for the impairment of gastrointestinal 
function in PD but abnormalities in the enteric nervous system within the gut itself have 
also been identified, including both Lewy-body formation and loss of dopaminergic neurons 
(Pfeiffer et al., 2003). 
Lewy body pathology in the myenteric plexus, leading to colonic sympathetic denervation, 
has long been recognized in patients with PD. Such pathologic changes are associated with 
prolonged intestinal transit time and constipation, symptoms believed to occur in ~80% of 
patients with PD (Jost et al., 1997). Recently, Politis et al. have suggested a dopaminergic 
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contribution to several non-motor symptoms of PD, including autonomic dysfunction and 
constipation (Politis et al., 2008). 
Apomorphine treatment can improve anorectal dysfunction in PD and suggests that 
abnormalities of defaecation and anorectal function could be a consequence of dopamine 
deficiency secondary to the pathological changes of PD (Chaudhuri et al., 2009). 
Medications used to treat the motor symptoms of PD (levodopa, anticholinergics) have even 
been implicated in further slowing of gastrointestinal motility and exacerbation of 
gastrointestinal dysfunction (Wood et al., 2010). 
6. Assessment of constipation 
A carefully taken history, including ongoing drugs and physical examination may be 
adequate in most cases. To perform more specific tests depend on single cases. It is possible 
to evaluate different aspects of bowel dysfunction. Measurement of whole gut transit time, 
swallowing a radio-opaque contrast medium, is the most widely used, non-invasive and 
inexpensive method to quantify large bowel function (Gill et al., 1994; Prokesch et al., 1999; 
Nicoletti et al., 1992; Evans et al., 1992). Anorectal function and pelvic floor incoordination 
can be assessed by anorectal testing, anorectal manometry and a balloon expulsion test. For 
instance, in this way it has been possible to demonstrate pelvic floor incoordination in MS 
patients (Diamant et al., 1999; et al., Weber 1987; Jameson et al., 1994; Chia et al., 1996). To 
evaluate distal colon innervation, electrical rectal sensory testing is a useful tool. It can 
distinguish between constipation connected to impaired central innervation of the gut or 
idiopathic form (Kamm et al., 1990). 
7. Pharmacological therapies 
Several drugs are available for patients with chronic constipation, ranging from older over-
the-counter laxatives to more recently developed prescription drugs (Lembo 2003; 
Longstreth 2006; Ramkumar et al., 2005; Rao et al., 2009; Tack et al., 2009; Tramonte et al., 
1997). Laxatives stimulate defecation by decreasing stool consistency and/or by stimulating 
colon motility. There are different classes of laxative drugs with different mechanism of 
action: osmotic laxatives and stimulant laxatives, bulking agents, stool softeners (Ramkumar 
et al., 2005; Tramonte et al., 1997). 
8. Fibers 
Fibers intake such as eating high-fiber foods (fruits, vegetables) or taking fiber/bulk 
supplements (bran, psyllium, methylcellulose or polycarbophil) is recommended during the 
initial treatment of constipation (Lembo et al., 2003; Locke et al., 2000). Unfortunately a long 
treatment (about 2-3 months) is required to obtain symptom relief. Despite the widespread 
use of fiber supplementation, this approach is effective in only a subset of patients and 
clinical trial supporting the use of increased fiber intake is limited. 
9. Osmotic laxatives 
Osmotic laxatives (poorly absorbed/non-absorbed sugars, saline laxatives and polyethylene 
glycol [PEG]) cause intestinal water secretion and may be recommended when fiber therapy 
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is ineffective (Lembo et al., 2003). Many osmotic laxatives require few days to be effective 
and can result in electrolyte and volume overload in patients with renal or cardiac failure 
(Lembo et al., 2003). Osmotic laxatives can induce abdominal cramping, bloating and 
flatulence. 
Osmotic agents are ions or molecules that are poorly absorbed by intestine and therefore 
they cause water retention in the intestinal lumen. Small intestine and colon are not able to 
keep an osmotic gradient between luminal contents and plasma, in contrast to stomach. 
Osmotic agents include: incompletely absorbed salts such as magnesium, sulphate and 
phosphate salts; sugar alcohols such as sorbitol or mannitol; poorly absorbed disaccharides 
such as lactulose and polyethylene glycol (PEG). 
These agents keep water in intestinal lumen, increasing stool frequency, softening their 
consistency and decreasing straining. Non-absorbable sugars induce little improvement in 
stool frequency and consistency, but they cause colonic fermentation and consequently 
bloating and abdominal distention. Sodium sulphate reduces water absorption, stimulating 
peristalsis. 
Bisodic phosphate is partially absorbed into the small bowel and it is well tolerated even if 
hyperphosphatemia can be observed as a consequence of overdose. 
Magnesium hydroxide and magnesium salts improve stool frequency and consistency. Their 
systemic absorption is limited and the most common side effects are electrolyte 
abnormalities (i.e. hypokalemia and sodium overload) and diarrhea. In this light, 
magnesium should be used with great care in patients with hearth or/and renal failure and 
in the elderly (Golzarian et al., 1994; Schiller et al., 2001; Spinzi et al., 2007). 
Lactulose is a complex sugar that is not digested and metabolized by bowel bacteria to form 
lactic, acetic and formic acids. In this way, it causes acidification of intestinal lumen, water 
secretion, production of H2 and CO2, and colon distension. Lactulose is very effective but 
induces flatulence and borborygmuses; moreover, its use should be avoided in patients with 
lactose intolerance. 
In a systematic review of controlled trials, PEG was more effective than lactulose (Lee-
Robichaud et al., 2010). PEG preparations are available with or without electrolyte 
supplements, and at different doses. 
Macrogol 3350 is a mixture of non-absorbable polymers with high molecular weight. It is not 
metabolized by bowel bacteria and it works as a pure osmotic agent by keeping water into 
colon, causing rehydration and softer stool. The amount of water and electrolytes carried by 
macromolecular structure of macrogol is related to dose. The presence of electrolytes 
reduces risk of electrolyte imbalance, increasing safety in patients with kidney diseases 
(Migeon-Duballet et al., 2006). Moreover, macrogol causes less flatulence compared to 
lactulose, and it is useful for treating chronic constipation and drug-induced constipation 
(Di Palma et al., 2007; Zangaglia et al., 2007). Preparations containing electrolytes can also be 
used with high water volumes intake, such as for colon cleansing prior to colonoscopy or 
surgery (Di Palma et al., 2002; Szojda et al., 2007). 
Glycerine is a well tolerated laxative, available just for rectal use. It works mainly by osmotic 
mechanism and stimulates evacuation lubricating stool. 
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Class Active principle Daily dose 
Latency effect 
(hours) 
Osmotic laxatives Magnesium citrate 18g 0.5-3 
 Magnesium 
hydroxide 
2-4 g 6-8 
 Magnesium sulfate 5-10g 6-8 
 
Sodium phosphate 
10-20 ml /os 
100ml/rectal
6-8 
0.5-3 
Sugars Lactulose 5-30g 24-48 
 Lactitol 10-15 g 24-48 
 Sorbitol 5-15 g 24-48 
 Mannitol 3-20 g 2-8 
 PEG 15-40 g 24-48 
 Glicerina 1-3 g 0.5 
Diphenylmethane 
derivatives 
Bysacodil 5-15 mg 10-12 
 Sodium picosolfate 5-15 mg 6-10 
Anthraquinone derivatives Senna 24-48 mg 6-12 
 Cascare 150-400 mg 6-12 
 Rhubarb 50-100 mg 6-12 
 Aloe 100-200 mg 6-12 
 Frangola 200-600 mg 6-12 
Surfactants Docusate sodium 240 mg 0.5 
Castor oil  15-60 ml 2-6 
Table 1. Classification of laxative drugs 
Stimulant laxatives (diphenylmethane and anthraquinone derivatives) produce rhythmic 
bowel contractions and should be recommended when osmotic laxatives fail (Borum et al., 
2001). These agents increase intestinal motility and secretion after few hours from ingestion, 
but they may cause severe side effects (e.g. abdominal cramps, rebound constipation, 
damage to intestinal smooth muscles or enteric nervous system, colorectal cancer risk, 
hyponatremia, hypokalemia, dehydration. (Borum et al., 2001; Lembo et al., 2003; Muller-
Lissner et al., 2005). 
Several drugs and herbal preparations induce defecation by different mechanisms and are 
called ‘stimulant’ laxatives because they are able to stimulate bowel motility (Geboes et al., 
1993). It is now clear that they have effect on mucosal transport as well as motility (Schiller 
et al., 1997). 
These agents include: surface active agents, such as docusate and bile acids; 
diphenylmethane derivatives, such as phenolphthalein and bisacodyl; ricinoleic acid; 
anthraquinones, such as senna and cascara. Senna and bisacodyl cause rhythmic 
contractions of intestinal muscles, increasing bowel motility; moreover they increase water 
secretion into bowel. Bisacodyl is hydrolyzed in both small intestine and colon into a free-
form that inhibits water absorption, but it also has an effect on enteric nervous system, 
inducing peristaltic response. Therefore, it should be avoided in patients with suspected 
intestinal obstruction. It is not clear whether these laxatives can induce damage to myenteric 
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plexus, whereas it is known that their chronic use is associated with colonic melanosis that is 
reversible with drug withdrawal (about 5-6 months). 
Bisacodyl and picosulfate are both phenylmethane prodrugs, hydrolysed by colonic bacteria 
or brush border enzymes to their active metabolite bis-(p-hydroxyphenyl)- pyridyl-2-
methane (BHPM) which stimulates peristalsis. 
The cathartic activity of bisacodyl and sodium picosulphate may depend on their 
conversion to compounds with free diphenolic groups (Sund et al., 1981). 
Phenolphthalein inhibits water absorption in small intestine and colon by effecting 
prostaglandins, kinins and the Na+K+-ATPase pump. Phenolphthalein is absorbed and can 
be undergone to an enterohepatic circulation which may prolong its effect. It has been 
withdrawn from sale in the United States because some studies in rodents suggested it may 
be carcinogenic (Garner et al., 2000; Josefson et al., 1997). Adverse reactions of derivatives of 
diphenylmethane are cramping and abdominal pain; high doses induce severe diarrhea, 
electrolyte depletion, damage to enterocytes, skin allergies and Stevens-Johnson syndrome 
(phenolphthalein). 
Docusates are ionic detergents which were designed to allow water to interact more 
effectively with stool solids, thereby softening stools. Bile acids are natural detergents that 
have been used as components of proprietary laxative preparations. If exogenous bile acid is 
taken orally, normal ileal absorptive capacity may be enormous and sufficient bile acid may 
get to the colon to reduce water and electrolyte absorption or to stimulate water secretion. 
Anthraquinones are a group of chemicals based on tricyclic anthracene nucleus. They are 
produced by different plants. Monoanthrones can form dianthrones and can be conjugated 
with sugars to yield glycosides. They are pro-drugs, not absorbed in small intestine and 
hydrolyzed by colon bacteria to active forms. The effects on water secretion with increased 
fecal water may appear about 6-8 hours after administration. These compounds are 
indicated to treat chronic constipation. Adverse drug reactions include allergies, loss of 
body fluid and electrolytes, reversible melanosis. 
The laxative action of Castor oil is due to an irritant action on tenuous intestine by rinoleic acid 
released by hydrolysis of triglycerides by pancreatic lipase. It has several action mechanisms: 
- Na+-K+-ATPase inhibition 
- cAMP levels increasing 
- mucose permeability increasing 
- NO synthesis 
Castor oil is used to preparation bowel for diagnostic or surgical procedures. Adverse 
reactions include abdominal-cramps and intestinal wall damage (e.g. erosion of the mucosa 
and epithelial desquamation). 
10. Stool softeners 
Laxatives which mostly soften or lubricate stools (e.g. sodium dioctyl sulfosuccinate and 
liquid paraffin) seem to be more effective than placebo to increase bowel movement 
frequency. Liquid paraffin, since it may interfere with absorption of fat-soluble vitamins, 
should be avoided in patients with oropharyngeal dysphagia (Gondouin et al., 1996). 
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11. Bulk lassatives 
Undigestible fibres attract water, causing larger and softer fecal mass, increasing bowel 
movements by 1.4 per week (Ramkumar et al., 2005; Tramonte et al., 1997). Fibres are 
usually well tolerated, although some symptoms, such as bloating, may get worse. 
12. Neuromuscular agents 
Some patients with colonic inertia seem to have a reduction in cholinergic nerve activity. 
This could be due to a damage to the enteric nervous system or to agents with anti-
cholinergic effects. In such instances it would be useful to increase cholinergic stimulation of 
colonic smooth muscle by supplying a cholinergic agonist agent. Bethanechol can be used 
for this purpose with good results in some patients. Neostigmine has recently been 
suggested as effective therapy for acute colonic pseudo-obstruction. 
13. 5-HT4 receptor agonists 
Serotonin (5-HT) is a regulator of gastrointestinal motility, secretion and sensitivity. 
Through 5-HT4 receptors, mainly expressed in enteric neurons, 5-HT triggers and 
coordinates intestinal peristalsis (Gershon et al., 2007). Cisapride, a 5-HT4 receptor agonist, 
is used to stimulate gastrointestinal motility in patients with gastro-esophageal reflux 
disease, functional dyspepsia and gastroparesis; in 2000, it was withdrawn from sale 
because of the occurrence of fatal arrhythmia’s through QT interval prolongation in patients 
with predisposing conditions (Tonini et al., 1999). 
Tegaserod, a 5-HT4 receptor agonist is shown to be effective for treatment of irritable bowel 
syndrome with constipation (Al-Judaibi et al., 2010). In 2007, Tegaserod was withdrawn 
from the commerce because of increased risk of cardiovascular adverse events such as 
myocardial infarction, unstable angina and stroke ( De Maeyer et al., 2008). 
Prucalopride, a 5-HT4 receptor agonist, is a highly selective compound. It enhances colonic 
transit in healthy control subjects and in patients with chronic constipation, in a dose-
dependent way (Bouras et al., 1999; Bouras et al., 2001; Camilleri et al., 2008; De Maeyer et 
al., 2008). It has been approved in Europe for the treatment of chronic constipation in 
women who do not respond to laxatives (2 mg). Recommended dose in elderly patients is 1 
mg for a larger bio-availability (Müller-Lissner et al., 2010). 
The misoprostol affects intestinal transit in healthy subjects and in patients with chronic 
constipation by stimulating water secretion and intestinal muscle contraction, especially in 
the left colon. Initial dosage should be 200 mcg twice/day, increased to 4/day, being sure it 
does not appear abdominal cramps. 
14. Colonic secretagogues 
Lubiprostone, the last drug approved by FDA for treatment of adult patients with chronic 
idiopathic constipation (Bethesda et al., 2006), is a gastrointestinal system-targeted bicyclic 
functional fatty acid that acts as a selective chloride channel (ClC-2) activator in the apical 
membrane of gastrointestinal epithelium to increase intestinal water secretion (Orr et al., 
2006; Winpenney et al., 2005). This enhanced secretion of chloride leads to an increased 
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intraluminal fluid amount, which facilitates transit in the intestine and thereby stool passage 
(Camilleri et al., 2006). 
Lubiprostone, approved by FDA in 2006, is not yet approved in Europe (Drossman et al., 
2009). Nausea, diarrhea and headache represent the most common adverse events, but 
patients also reported abdominal distension, abdominal pain and flatulence. Nausea can be 
reduced taking lubiprostone with food (Bethesda et al., 2006). 
Linaclotide is a 14-amino acid peptide analog of guanylin and acts as an agonist at the 
luminal guanylin receptor on enterocytes, the guanylate cyclase-C receptor, which induces 
intestinal chloride and fluid secretion through cyclic GMP production (Bharucha et al., 
2010). It is not yet approved for treatment of chronic constipation (Kurtz et al., 2006). 
The mixed 5-HT4 receptor agonist/5-HT3 receptor antagonist renzapride relieves symptoms 
of constipation by softening stool consistency and increasing colonic transit. It has been 
tested only in patients with irritable bowel syndrome and constipation (Camilleri et al., 
2004). Other 5-HT4 agonists, such as norcisapride and mosapride (Cremonini et al., 2005), 
neurotrophic factors (Coulie et al., 2000) and probiotic agents (Koebnick et al., 2003; 
Ouwehand et al., 2002) are also under investigations. Additional works are needed to 
determine their role in the treatment of chronic constipation. 
Neurotrophins stimulate the development, growth and function of the nervous system, and 
increase colonic transit when administered subcutaneously in healthy subjects and patients 
with chronic constipation (Coulie et al., 2000). 
Colchicine, usually used in the treatment of acute gout, induces diarrhea through an 
unknown dose-dependent mechanism. Colchicine increases stool frequency and reduces 
number of rescue laxatives needed. In a controlled trial, colchicine (1 mg/day) improved 
constipation in patients with slow transit (Taghavi et al., 2010). 
15. Opiate antagonists 
Opiate antagonists have also been suggested to treat constipation. These agents block opiate 
receptors in intestine avoiding mucosal absorption and inhibition of intestinal transit, 
caused by opiate. Thus mucosal absorption should be reduced and intestinal transit should 
be increase by the administration of drugs like naloxone and naltrexone. An early report 
suggested a role for this type of agent in idiopathic constipation, but a successive report 
denied it (Ragavan et al., 1983; Fotherby et al., 1987). 
Opiate antagonists are useful in patients with opiate-induced constipation (Meissner et al., 
2000; Yuan et al., 2000). The opiate antagonists methylnaltrexone and alvimopan are under 
investigation for the treatment of opiate-induced constipation and postoperative ileus, but 
unlike other opiate antagonists, they do not have any impact on central analgesia (Camilleri 
et al., 2005; Yuan et al., 2004). Their usefulness in treating non-opioid-induced constipation 
remains unclear. 
16. Management of constipation in neurological disorders 
Managing bowel function is a main concern in neurological patients, having an impact equal 
to mobility impairment on quality of life (Norton  et al., 2010). It is important to get 
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information on current bowel status in order to provide an effective treatment (Gulick et al., 
2011). The frequent coexistence of faecal incontinence represents a challenge in the 
management of constipation (Hinds et al., 1990). On the other hand, treatment of 
constipation is essential, because constipation itself may worsen bladder symptoms (Hinds 
et al., 1989). Treatment of bowel dysfunction in MS patients is often empirical and there are 
a few studies comparing the efficacy of different measures such as high fibre diet, adequate 
intake of fluids, bowel habits, physical exercise and the use of medication (Winge et al., 
2003). 
Increasing dietary fibre may be useful in MS patients to soften faeces, but it is not helpful in 
patients with severe constipation, as observed in spinal cord injury (Cameron et al., 1996). 
Furthermore the need for adequate fluid intake when taking bulking agents should be 
strongly encouraged. Sufficient or additional fluid intake and the use of docusate stool 
softener (up to 600 mg/day) are simple ways to help maintain soft bowel movements 
(DasGupta et al., 2003). On the other hand, a high fibre diet or the use of bulking agents may 
produce increased symptoms connected to the presence of increased fermentable substrate if 
peristalsis is impaired (Winge et al., 2003; Muller et al., 1988). 
Stimulant or osmotic laxatives are useful when transit is slow. Senna and bisacodyl are 
effective and their dose can be modulated in order to avoid faecal incontinence, an effect 
reported more frequently with osmotic laxatives (Gattuso et al., 1994; Schiller et al., 1999). 
Rectal stimulants such as glycerine or bisacodyl suppository, sodium citrate micro-enema or 
phosphate enema, have the advantage of predictability in terms of time of response as 
observed in patients with spinal cord injury or stroke (House et al., 1997; Munchiando et al., 
1993). 
Pelvic floor incoordination has been observed in MS patients (Mathers et al., 1990; Weber et 
al., 1987; Chia et al., 1996). Behavioural therapies – the so called biofeedback - have an 
important role in the management of constipation in this group of patients and they are 
effective in subjects with mild to moderate disability and a non progressive disease course. 
Over a third of patients considered themselves to have benefited in the medium term, but 
long term effects of biofeedback are unknown. There are no physiological test that can 
predict the response to this treatment (Wiesel et al., 2000; Munteis  et al., 2008). Biofeedback 
improves pelvic floor function, conditioning the voluntary striated muscle sphincter 
response and patient’s consciousness of a stimulus distending the rectum (Wiesel et al., 
2000; Storrie et al., 1997). 
Recently, in a randomized controlled study, some authors have suggested a beneficial effect 
of abdominal massage on constipation symptoms in MS patients (McClurg et al., 2011). 
Abdominal massage decreases severity of constipation and abdominal pain, and increases 
bowel movements. In health subjects with constipation, the massage has a delayed effect 
that may occur first after a number of weeks so that it is considered a long-term treatment. It 
does not lead to decrease in laxative intake, so abdominal massage could be a complement 
to medication rather than a substitute (Lämås et al., 2009). 
For selected patients with severe constipation, when there is a lack of response to 
conservative therapies, colostomy or the Malone appendicostomy can be contemplated 
(Wiesel et al., 2001; Hennessey et al., 1999; Krogh  et al., 2009). 
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In stroke patients Early physical activity should be recommended for stroke patients to 
prevent new-onset constipation (Su et al., 2009). The establishment of dedicated stroke units 
with early mobilisation, rehydration and diet regulating measures have resulted in a 
remarkable reduction of the problems related to constipation in stroke patients (Winge et al., 
2003; Cardin et al., 2010; Kumar et al., 2010). A systematic assessment of bowel habits by 
nursing staff with a simple practice-based approach towards bowel management and 
patient/caregiver education has been shown to be helpful in patients with stroke (Harari et 
al., 2004). 
A step by step approach, from simple to more complex treatment measures, is strongly 
recommended also in PD patients. Increasing daily fibre and fluid intake is the first step, 
since it is deficient in many patients with PD. Fibre supplements with psyllium or 
methylcellulose is useful and it significantly increases stool frequency and weight. The 
second step is to add a stool softener, such as docusate. Then patient can use an osmotic 
laxative, such as lactulose or sorbitol. Also the regular use of polyethylene glycol electrolyte 
balanced solutions is effective. It would be better to avoid irritant laxatives and enemas, 
even if they could be useful in selected cases (Pfeiffer et al., 2003). 
Intrajejunal infusion of duodopa in patients with advanced-stage PD determine an 
improvement in constipation and other bowel symptoms in addition to other non-motor 
symptoms (Chaudhuri et al., 2009). Treatment of defecatory dysfunction in PD is more 
demanding. Laxatives do not improve the impaired anorectal muscular coordination and 
may increase the problem. Dopaminergic drugs may be useful, being observed an 
improvement in anorectal manometric during “on” periods, with deterioration when “off”’ 
(Pfeiffer et al., 2003). Also apomorphine therapy can improve anorectal dysfunction in PD 
(Chaudhuri et al., 2009). Botulinum-toxin injections into the puborectalis muscle have been 
used successfully in the treatment of parkinsonian defecatory dysfunction. Faecal 
incontinence is a potential complication. Behavioural treatment approaches such as 
biofeedback training have not been specifically investigated in PD (Pfeiffer et al., 2003). 
17. Conclusions 
Bowel dysfunction is a frequent complication in neurological disorders and it can be due to 
neurological lesions or non-neurological causes. Owing to a complex physiopathology and 
to the involvement of autonomic system, a specific treatment is limited. A multimodal 
approach is needed to manage symptoms successfully and to provide individualized care 
for a particular patient. It is essential to determine realistic aims. Training bowel habits 
associated with physical activity, proper use of medication and biofeedback, just for selected 
patients, is an effective strategy to improve constipation in neurologic patients for some 
time, depending largely on disability level. Bowel management is still often empirical in 
neurological disorders and well-designed controlled trials are needed. 
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